levoflunarizine

Levoflunarizine is the levo-enantiomer (S-isomer) of flunarizine, a selective calcium channel blocker. Developed by Beijing Fourth Ring Pharmaceutical, it is an investigational small molecule being evaluated for the treatment of vertigo associated with posterior circulation ischemic stroke. Like its parent compound flunarizine, levoflunarizine acts as an antagonist of voltage-gated calcium channels, which is thought to reduce vestibular excitability and improve cerebral microcirculation. The drug is currently in Phase 2 clinical development in China, where it is being studied in a tablet formulation to assess its efficacy, safety, and pharmacokinetic profile in adult patients.

Other names

levo flunarizinelevo flunarizine hydrochloride(S)-flunarizine